Edison International Common Stock vs Smith & Nephew plc — how do they compare? Edison International Common Stock trades at $55.16 (market cap $20.90B), while Smith & Nephew plc trades at $27.05 (market cap $11.10B). The key difference: Edison International Common Stock is the larger of the two by market cap, and Edison International Common Stock pays the higher dividend (6.46%). Which is the better fit depends on your goals — on Pluang, investors hold Edison International Common Stock for 0 Days and Smith & Nephew plc for 120 Days on average.
| EIX | SNN | |
|---|---|---|
Market Cap | $20.90B | $11.10B |
Volume | 7,556,718 | 1,051,703 |
Sector | Utilities | Health |
52-Week High | $80.38 | $37.17 |
52-Week Low | $51.47 | $26.42 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $64.28B | $14.13B |
Dividend Yield | 6.46% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Edison International is the parent company of Southern California Edison, an electric utility that supplies and delivers electricity across Southern California. It also owns Trio, an energy advisory business.
Read more on EIX →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →